Company news

Cannabis Bioscience International Holdings, Inc. news in 2026

Cannabis Bioscience International Holdings, Inc.'s news releases, calls and decks from 2026, newest first.

View company

CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine

October 19, 2026

CBIH Unveils Cannabinoid-Based Intranasal Platform for Alzheimer's Research

July 20, 2026

Years of Preparation. One Regulatory Approval. Commercial Launch Begins: CBIH Receives Texas License for Consumable Hemp Products

July 15, 2026

CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings

July 6, 2026

Cannabis Bioscience International Holdings Opens New Revenue Pathway with First VitaCookies Licensing Agreement

June 22, 2026

CBIH Announces Patent-Related Scientific Framework for PTSD-Focused Cannabinoid and Psilocybin Research

June 15, 2026

CBIH Advances Strategic Pathway to Bring VitaCookies' Science-Driven Functional Wellness Platform to Texas Consumers

June 8, 2026

CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation

June 1, 2026

Cannabis Bioscience International Holdings Seeks Participation in Renewed DEA Marijuana Rescheduling Hearing

May 13, 2026

CBIH Evaluates a Potential Reg A Offering of Approximately $1,000,000 to Enable Commercial Launch, Statewide Educational Expansion, and Protection of Its Patent Portfolio

January 21, 2026

CBIH Puts CMS at the Center of the Board: Formal Coordination with Dr. Mehmet Oz's Team and an "Evidence Sprint 2026" Focused on Grants, Research and Clinical Evidence

January 12, 2026

CBIH Launches Federal and Pharmaceutical Outreach Initiative to Accelerate Medical Cannabis Research in the Schedule III Transition

January 5, 2026